BRAF
BRAF is a serine/threonine kinase involved in the MAPK signaling pathway. Activating mutations, particularly V600 alterations, are actionable drivers in melanoma, colorectal cancer, and other solid tumors.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where BRAF is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Anaplastic Thyroid Cancer (ATC) Solid Tumor · Thyroid |
| |
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
| |
Low-Grade Glioma Solid Tumor · Brain |
| |
Melanoma Solid Tumor · Melanoma |
| |
Metastatic Colorectal Cancer (mCRC) Solid Tumor · Colorectal |
| |
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung |
|
Approvals defined at the solid tumor level where BRAF is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report BRAF as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports BRAF as part of its biomarker panel.
Reports BRAF as part of its biomarker panel.
Reports BRAF as part of its biomarker panel.
Reports BRAF as part of its biomarker panel.
Reports BRAF as part of its biomarker panel.
Reports BRAF as part of its biomarker panel.